CNTX — Context Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1842952 ·
Last close
$0.65
Market Cap
$59.99M
52W High
$3.12
52W Low
$0.55
ADV30
3,656,654
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,343,799 | -8,680,572 | 58,859,093 | 54,528,596 | 6,656,718 |
| Dec 2025 | 0 | — | -13,804,646 | -13,025,607 | 68,493,768 | 65,995,228 | 8,020,041 |
| Sep 2025 | 0 | — | -10,610,480 | -9,693,237 | 79,231,160 | 76,938,183 | 6,056,994 |
| Jun 2025 | 0 | — | -9,758,362 | -8,827,510 | 87,152,101 | 83,517,047 | 4,607,779 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,385,380
Investing CF
$-2,033,948
Financing CF
$-15,268
CapEx
$-2,033,948
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.46
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-130,903,309
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-39,702,631
Pretax Income TTM
$-36,123,615
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -39,702,631 | -36,123,615 | 68,493,768 | 8,020,041 | — | -26,385,380 |
| Dec 2024 | 0 | -29,923,900 | -26,725,104 | 98,126,759 | 2,860,497 | — | -14,556,434 |
| Dec 2023 | 0 | -25,072,616 | -23,964,211 | 16,062,735 | 4,191,715 | — | -21,047,618 |
| Dec 2022 | 0 | -14,881,203 | -14,835,939 | 37,965,943 | 3,207,577 | — | -13,549,234 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$840,150
NetIncome TTM
$-13,426,294
OpCashFlow TTM
$0
Assets (Latest)
$98,126,759
Forward EPS
$-0.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | $59.83M | $9.10 | — |
| BYSI | BeyondSpring Inc. | $59.21M | $1.44 | — |
| MCRB | Seres Therapeutics, Inc. | $59.17M | $6.11 | — |
| CLCS | Cell Source, Inc. | $58.48M | $0.86 | — |
| IMMP | IMMUTEP Ltd | $61.75M | $0.42 | — |
News headlines (Yahoo Finance, 1h cache)
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 20:05 · Yahoo
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-07-06 20:07 · Yahoo
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish
2026-07-05 22:08 · Yahoo
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip
2026-06-15 21:20 · Yahoo
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
2026-06-15 15:10 · Yahoo
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
2026-06-15 10:30 · Yahoo
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
2026-05-27 11:30 · Yahoo
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 10:45 · Yahoo
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
2026-05-06 20:18 · Yahoo
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock
2026-04-27 14:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.